AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34498818
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg of carbohydrate (CHO)
Trial: 34498818
Drug: 0.6 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 g/kg of carbohydrate with 6 mg/kg of caffeine (CAF+CHO)
Trial: 35229960
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nicotine delivered over 1 min
Trial: 35229960
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg nicotine delivered over 2.5 min
Trial: 35229960
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nicotine delivered over 5 min
Trial: 35229960
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nicotine delivered over 10 min
Trial: 35229960
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg nicotine/min
Trial: 35229960
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg nicotine/min
Trial: 35229960
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg nicotine/min
Trial: 35229960
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nicotine/min
Trial: 35785593
Drug: Daily teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily teriparatide
Trial: 35785593
Drug: Weekly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly high-dose teriparatide
Trial: 35027397
Drug: Vector vaccine
RxNorm normalized name: COVID-19 non-replicating viral vector vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vector vaccine ChAdOx1 nCoV-19 (Oxford-AstraZeneca)
Trial: 35027397
Drug: mRNA vaccine
RxNorm normalized name: RSV mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA vaccine (homologous)
Trial: 34928302
Drug: Vector vaccine
RxNorm normalized name: COVID-19 non-replicating viral vector vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vector vaccine
Trial: 39749328
Drug: mRNA vaccine
RxNorm normalized name: RSV mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA vaccine
Trial: 32866440
Drug: Tocilizumab 162
RxNorm normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 162 mg subcutaneously weekly for 48 weeks
Trial: 36598543
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg CBD
Trial: 35851700
Drug: Oral food
RxNorm normalized name: Nutritional Supplement Oral Food, Solid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral food challenges
Trial: 34393202
Drug: Analgesic treatment
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic treatment
Trial: 33802012
Drug: HMB complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB complex (2.4 g of HMB + 14 g of glutamine + 14 g of arginine)
Trial: 33802012
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (glutamine complex, 7.2 g of protein including 6 g of glutamine)
Trial: 37650921
Drug: Curcumin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1 g) with piperine (5 mg) twice daily
Trial: 32235946
Drug: Cawthorne‐Cooksey exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cawthorne‐Cooksey exercises and simple balance exercises (15 min, twice a day, unsupervised)
Trial: 33866270
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: TV 6 ml/kg, PEEP 5 cmH20
Trial: 33866270
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: TV 6 ml/kg, PEEP 8 cmH20
Trial: 33866270
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: TV 8 ml/kg, PEEP 5 cmH20
Trial: 33866270
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: TV 8 ml/kg, PEEP 8 cmH20
Trial: 33949001
Drug: r‐ATG 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐ATG 2.5 mg/kg
Trial: 33949001
Drug: r‐ATG 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐ATG 3.5 mg/kg
Trial: 33284903
Drug: Phosphate-buffered saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate-buffered saline solution (negative control)
Trial: 36412376
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy for 30 min, 3 days/week for 4 weeks
Trial: 32008198
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch (RS) supplementation (16 g RS/day)
Trial: 35948873
Drug: REACH intervention
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REACH intervention (text message‐delivered self‐management support focusing on medication adherence, diet, and exercise)
Trial: 33276298
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic use in neonatal lambs
Trial: 32151119
Drug: Oral/enteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral/enteral nutrition plus pantoprazole
Trial: 32151119
Drug: Oral/enteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral/enteral nutrition only
Trial: 35460853
Drug: Anesthesia administered
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia administered
Trial: 32522414
Drug: 0.1‐mL ID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1‐mL ID injection of purified Vero cell rabies vaccine (PVRV) on days 0 and 28
Trial: 32522414
Drug: 0.5‐mL intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐mL intramuscular PVRV on D0, D7 and D28
Trial: 36184275
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) infusion following hysteroscopic adhesiolysis
Trial: 33028555
Drug: Varenicline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline and nicotine replacement therapy (NRT) lozenges
Trial: 33028555
Drug: Varenicline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline and placebo lozenges
Trial: 34135056
Drug: Intraoperative wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative wound irrigation with aqueous 10% povidone–iodine solution (40 mL for 1 min before skin suture)
Trial: 34135056
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (100 mL for 1 min before skin suture)
Trial: 32134735
Drug: Zinc deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc deficiency defined as serum zinc level < 75 μg/dL
Trial: 32081593
Drug: Low Intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Intensity Laser Therapy (LILT) applied on the experimental side on the 1st, 3rd, 5th, 7th, 14th and 15th days consecutively.
Trial: 32081593
Drug: Low Intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Intensity Laser Therapy (LILT) at the end of canine retraction (4.5 months).
Trial: 36247106
Drug: Weekly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly group singing for 12 weeks
Trial: 35012462
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (GTN) 5 mg daily for 4 days
Trial: 32998005
Drug: β-blockers (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers (high-dose, medium-dose, low-dose)
Trial: 32998005
Drug: Medium-dose β-blockers
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose β-blockers
Trial: 32998005
Drug: Vasodilating β-blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasodilating β-blockers
Trial: 32740976
Drug: Experimental attention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Experimental attention remediation treatment
Trial: 35331535
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea infusion with standardized breakfast
Trial: 32696033
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of benzathine penicillin G
Trial: 32696033
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of benzathine penicillin G
Trial: 34081196
Drug: Direct Oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulants (DOAC) treatment prior to lockdown
Trial: 34081196
Drug: Direct Oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulants (DOAC) treatment during lockdown
Trial: 34902081
Drug: Trichoderma asperellum
RxNorm normalized name: Trichoderma harzianum
DrugBank: Trichoderma harzianum (DB10703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trichoderma asperellum (quality and organic seed-treatment products)
Trial: 33947295
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg/mL administered via prefilled syringe (PFS)
Trial: 33947295
Drug: Risankizumab 150
RxNorm normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 150 mg/mL administered via autoinjector (AI)
Trial: 36574828
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg)
Trial: 35955123
Drug: Cognitive‐behavioral smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral smoking cessation treatment along with an App with active therapeutic components (SinHumo App)
Trial: 35955123
Drug: Cognitive‐behavioral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral treatment along with the use of a control App (without active components)
Trial: 37833472
Drug: Hydromorphone 2
RxNorm normalized name: HYDROmorphone 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone 2 mg
Trial: 36263927
Drug: Fosnetupitant 235
RxNorm normalized name: fosnetupitant 235 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosnetupitant 235 mg infusion
Trial: 36263927
Drug: Fosnetupitant (17.6–353
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosnetupitant (17.6–353 mg) infusion
Trial: 32504593
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy plus LDFRT (0.5 Gy twice daily for 2 days)
Trial: 32504593
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy alone
Trial: 35755061
Drug: Height-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Height-based dosing algorithm of bupivacaine
Trial: 35755061
Drug: Constant dose
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant dose of bupivacaine (Conventional group)
Trial: 34655135
Drug: FITOPROT (mucoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FITOPROT (mucoadhesive phytomedication containing curcuminoids and Bidens pilosa L.)
Trial: 32352644
Drug: Dapagliflozin up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin up to 10 mg once daily
Trial: 34251414
Drug: Cytarabine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine (100 mg/m2 per day on days 4-10) and Daunorubicin (60 mg/m2 per day on days 4-6) followed by Cytarabine consolidation (2000 mg/m2 per day on days 4-8) with G3139 (7 mg/m2 per day on days 1-10 for induction or days 1-8 for consolidation)
Trial: 34251414
Drug: Cytarabine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine (100 mg/m2 per day on days 4-10) and Daunorubicin (60 mg/m2 per day on days 4-6) followed by Cytarabine consolidation (2000 mg/m2 per day on days 4-8) without G3139
Trial: 34251414
Drug: Cytarabine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine (100 mg/m2 per day on days 4-10) and Daunorubicin (60 mg/m2 per day on days 4-6) followed by Cytarabine consolidation (2000 mg/m2 per day on days 4-8) with G3139
Trial: 34664868
Drug: Carbohydrate group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate group (400 mL carbohydrate drink 2 hours before surgery)
Trial: 35112455
Drug: Relaxing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxing the UACR criterion from 300 mg/g to 210 mg/g
Trial: 33820541
Drug: Warming blanket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming blanket and infusion thermometer
Trial: 32320566
Drug: Ruxolitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (10 mg twice daily)
Trial: 33861741
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (directly observed treatment)
Trial: 33861741
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (referral for topical treatment)
Trial: 34388395
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (800 μg twice daily for 14 days)
Trial: 32962674
Drug: SIB-IMRT (60.62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIB-IMRT (60.62 Gy equivalent dose in 2-Gy fractions)
Trial: 32962674
Drug: SIB-IMRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIB-IMRT + concurrent chemotherapy (weekly paclitaxel and a platinum-based drug for 5-6 weeks)
Trial: 32962674
Drug: SIB-IMRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIB-IMRT + concurrent chemotherapy
Trial: 32841739
Drug: Buccal Micronucleus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal Micronucleus Cytome Assay (BMCyt)
Trial: 36220069
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TRE and LCD
Trial: 32819394
Drug: Home-based contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based contraceptive delivery (condoms, pills, injection, implant) during the routine 40-day postpartum visit.
Trial: 33544337
Drug: Comparator EGFR
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator EGFR TKI (gefitinib 250 mg once daily or erlotinib)
Trial: 33275096
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin alone
Trial: 33275096
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin plus graduated compression stockings
Trial: 36990261
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation (OAC) treatment
Trial: 32053630
Drug: Moderate NPK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate NPK treatment (50 kg N + 10 kg P + 50 kg K /ha)
Trial: 32053630
Drug: High NPK
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NPK treatment (100 kg N + 25 kg P + 100 kg K /ha)
Trial: 32053630
Drug: Potassium only
RxNorm normalized name: Potassium only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium only treatment (50 kg K/ha)
Trial: 35776034
Drug: Quercetin-containing supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin-containing supplement (200 mg daily for 4 weeks)
Trial: 35383823
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (16,800 IU vitamin D3 once a week for 1 year) in subgroup with 25(OH)D concentrations of 15-25 nmol/L (n=31)
Trial: 35383823
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in subgroup with 25(OH)D concentrations of 15-25 nmol/L (n=31)
Trial: 34956849
Drug: Structured education
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured education on TB-DM combined with clinical monitoring and medication adjustment
Trial: 32378932
Drug: Online intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online intervention for alcohol use and PTSD (details on dosage and duration not available)
Trial: 36397390
Drug: Midazolam 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.06 mg/kg (M2)
Trial: 32565073
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg doxycycline
Trial: 33356547
Drug: Deterra Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deterra Drug Deactivation System deactivation pouches
Trial: 33499754
Drug: modified directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified directly administered antiretroviral therapy (mDAART)
Trial: 34673536
Drug: Self-administered high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered high-intensity interval training guided by smartphone app (AG)
Trial: 34766589
Drug: 2000 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU/day of oral cholecalciferol (vitamin D)
Trial: 32841433
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg pycnogenol taken orally twice a day for 60 days
Trial: 32841433
Drug: Placebo taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken orally twice a day for 60 days
Trial: 616769481
Drug: Lidocaine 20
RxNorm normalized name: lidocaine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 20 mg IV
Trial: 616769481
Drug: Lidocaine 20
RxNorm normalized name: lidocaine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 20 mg and Ketorolac 10 mg IV
Trial: 35738656
Drug: HMB-enriched nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-enriched nutritional supplements (65 g/day)
Trial: 32211776
Drug: Negative HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative HBV RNA and HBcrAg < 4 log10 U/mL at end of treatment (EOT)
Trial: 32211776
Drug: Positive HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive HBV RNA and HBcrAg ≥ 4 log10 U/mL at EOT
Trial: 32211776
Drug: Negative HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative HBV RNA and HBcrAg < 4 log10 U/mL at EOT
Trial: 32211776
Drug: Entecavir or
RxNorm normalized name: entecavir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir or tenofovir before discontinuation (validation cohort)
Trial: 33991482
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all information
Trial: 36382987
Drug: Tazarotene 0.045%
RxNorm normalized name: TAZAROTENE 0.045% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.045% lotion
Trial: 33683083
Drug: Vehicle lotion
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle lotion
Trial: 34624047
Drug: Lifestyle medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle medicine group (LM group)
Trial: 32344285
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone administration (levothyroxine and liothyronine)
Trial: 35312970
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with luseogliflozin 2.5 mg once daily and semaglutide 0.5 mg once per week
Trial: 35312970
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with semaglutide
Trial: 32826450
Drug: Thin-strut drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin-strut drug-eluting stent (DES)
Trial: 32826450
Drug: Thick-strut drug-eluting
RxNorm normalized name: tick-borne encephalitis purified antigen Prefilled Syringe [Ticovac]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thick-strut drug-eluting stent (DES)